With the booming development of natural anticancer agents, icaritin has been widely used in clinical liver cancer treatment due to the smaller number of side effects. Among them, enzymes as catalysts for producing icaritin have attracted considerable attention. Industrial production remains in its infancy due to the poor reusability of free enzymes, despite enzymes possessing favorable efficiency and green catalytic effects. The present study investigated two immobilization methods, including cross-linked enzyme aggregates (CLEAs) and magnetic cross-linked enzyme aggregates (MCLEAs). The optimal temperature and pH for the two hydrolases were determined, followed by characterization using VSM, XRD, FT-IR, and TEM techniques. The experiments have demonstrated that MCLEAs eradicate the need for ultrafiltration; MCLEAs are beneficial for enhancing fixation efficiency. Additionally, MCLEAs exhibited significantly higher catalytic activity, which raised the catalytic activity by approximately 30% compared with CLEAs. Moreover, after 10 consecutive reuse cycles, the catalytic activity of MCLEAs remained above 70%, maintaining a conversion rate of epimedin C at 61.59%. To summarize, MCLEAs offer an efficient strategy for enzyme immobilization. MCLEAs not only significantly enhanced both the enzyme’s ability to catalyze and resist but also eliminated the necessity for ultrafiltration as well as enabled rapid product separation.
Background: Traditional Chinese Medicine categorizes melasma into various syndromes, one of which is the kidney-deficiency and blood-stasis syndrome. Different Chinese medicines are used for each syndrome to achieve a personalized treatment approach, resulting in a more effective outcome. The study aimed to investigate the efficacy and safety of Lutai Danshen Baishao Granules (LDBG) in alleviating melasma and to compare the effects of LDBG in patients with and without kidney-deficiency and blood-stasis syndrome through a real-world, large-sample investigation. Methods: A multicenter, prospective, nonrandomized, observational trial was conducted from December 2021 to May 2023, recruiting 1000 female participants with melasma. After enrollment, participants were divided into Group A (kidney-deficiency and blood-stasis syndrome) and group B (non-kidney-deficiency and blood-stasis syndrome) based on the traditional Chinese medicine (TCM) syndrome scale. General physical signs, melasma indicators, Dermatology Life Quality Index, and TCM syndrome scores were recorded before and after the intervention. The long-term effectiveness was assessed 2 months after the intervention ended. Results: Following the intervention, melasma-related indicators and TCM syndrome scores were significantly lower than those before the intervention (P < .001). Compared to Group B, Group A showed a more significant reduction in the total area of melasma and the Melasma Area and Severity Index score (P < .05). The reduction in melasma area was also more pronounced in Group A (group A: 425.00 vs group B: 312.50, P < .001). Two months after the intervention, intergroup and intragroup comparisons revealed that LDBG had a long-term effect with a lower tendency for recurrence, and the long-term effect in Group A was better than in group B (P < .05). The overall incidence of adverse events during the trial was 1.2%. Conclusion: LDBG can reduce facial melasma and improve TCM syndromes, particularly in cases of melasma associated with kidney-deficiency and blood-stasis syndrome, with high safety and low risk of relapse.